Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
23.76
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
↗
December 20, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
↗
November 10, 2023
Via
Benzinga
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
November 06, 2023
Via
Investor Brand Network
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Top Picks 2024: Celldex Therapeutics, Inc.
↗
January 28, 2024
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to...
Via
Talk Markets
Top 4 Health Care Stocks That May Crash This Month
↗
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 27, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
↗
November 17, 2023
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.
Via
InvestorPlace
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
↗
November 08, 2023
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share.
Via
Benzinga
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Why Celldex Therapeutics Blasted 13% Higher on Monday
↗
November 06, 2023
The biotech's CSU treatment advanced in the laboratory.
Via
The Motley Fool
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
↗
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...
Via
Benzinga
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
↗
November 06, 2023
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 06, 2023
Via
Benzinga
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 05, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 25, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
↗
August 27, 2023
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
↗
August 22, 2023
Via
Benzinga
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 11, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
July 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 10, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
